Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sacituzumab govitecan + rezvilutamide
- Development stage
- Unknown
- Lead developer
- Null
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
A1:SG + SHR3680 is a combination therapy being evaluated in the Future-Trop2 umbrella trial for the first-line treatment of locally advanced or metastatic triple-negative breast cancer (TNBC), specifically targeting the luminal androgen receptor (LAR) subtype. The combination consists of sacituzumab govitecan, a TROP-2-directed antibody-drug conjugate (ADC) carrying an SN-38 payload, and rezvilutamide (SHR3680), a second-generation small molecule androgen receptor (AR) antagonist. This precision medicine approach aims to leverage the high expression of TROP-2 in TNBC while simultaneously inhibiting the androgen signaling pathway that drives the LAR subtype. Sacituzumab govitecan provides targeted delivery of a cytotoxic topoisomerase I inhibitor, while rezvilutamide blocks the growth-promoting effects of androgens in AR-positive breast cancer cells.
- Brand names
- TrodelvyAiruijie
- Other names
- sacituzumab govitecan + SHR3680SG + SHR3680
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)AR (Adrenergic receptors)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on sacituzumab govitecan + rezvilutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sacituzumab govitecan + rezvilutamide.